Dr. Chung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6201 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-633-5555Fax+1 469-291-2736
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
- Massachusetts General HospitalResidency, Internal Medicine, 2006 - 2009
- Washington University in St. Louis School of MedicineClass of 2006
- Cornell UniversityB.A., Biology, Concentration in Biochemistry, 2001
Certifications & Licensure
- TX State Medical License 2018 - 2026
- NY State Medical License 2009 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Tito Bastianello Young Investigator Award MDS Foundation, 2017
- Paul Sherlock Housestaff Teaching Award, Department of Medicine MSKCC, 2017
- Early Career Award in Myelodysplastic Syndrome Research Dresner Foundation, 2017
- Join now to see all
Publications & Presentations
PubMed
- 84 citationsCardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.Bimalangshu R. Dey, Stephen S. Chung, Thomas R. Spitzer, Hui Zheng, Thomas E. MacGillivray
Transplantation. 2010-10-27 - 1836 citationsEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaMarco L. Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae H. Park
Science Translational Medicine. 2014-02-19 - 24 citationsCD97 is a critical regulator of acute myeloid leukemia stem cell function.Gaëlle H. Martin, Nainita Roy, Sohini Chakraborty, Alexis Desrichard, Stephen S. Chung
The Journal of Experimental Medicine. 2019-10-07
Journal Articles
- CD99 is a Therapeutic Target on Disease Stem Cells in Myeloid MalignanciesChung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, Levine RL, Carroll M, Klimek VM, Melnick AM, Park CY, Sci Transl Med, 1/1/2017
- MicroRNA Dysregulation in the Myelodysplastic SyndromesChung SS, Park CY, MicroRNA, 1/1/2013
- A 75- year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma)Baikaidi M, Chung SS, Tallman MS, Damon LE, Walker AR, Marcucci G, Sholi AM, Morris GJ, Semin Oncol, 1/1/2012
- Join now to see all
Books/Book Chapters
Lectures
- An Analysis of the Transcriptional Response of Myelodysplastic Syndrome Stem Cells to Therapy at Single Cell Resolution.1/1/2017
- An Analysis of the Transcriptional Response of Myelodysplastic Syndrome Stem Cells to Therapy at Single Cell Resolution. Session 636. Myelodysplastic Syndromes- Basic...1/1/2016
- CD99 is a Therapeutic Target on Disease Stem Cells in the Myelodysplastic Syndromes and Acute Myeloid Leukemia. Session 6: The Myelodysplastic Syndromes.1/1/2014
- Join now to see all
Press Mentions
- Breakthrough Research Studies Are Unveiled at the MDS Foundation 14th International Symposium on Myelodysplastic SyndromesMay 8th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: